HK-listed gold stocks jump as US economic fears boost bullion prices
On Tuesday, Canaccord Genuity maintained a Buy rating for Passage Bio Inc. (NASDAQ: PASG) stock with a steady price target of $13.00.
The firm's analyst highlighted positive interim data from the upliFT-D Phase 1/2 study, noting an increase in the biomarker CSF PGRN over time, particularly in a patient with approximately 12 months of follow-up.
This contrasts with competing data from another study, which indicated a decline in CSF progranulin levels at the 12-month mark in a low dose cohort.
The safety profile of PBFT02, the gene therapy being tested by Passage Bio, has remained uneventful, with the firm mentioning that the immunosuppression adjustments previously discussed have not led to any new safety concerns.
The analyst expressed satisfaction with the results at this stage of the trial and anticipates more data in the first half of 2025, which could further establish the therapy's clinical profile and competitive position.
The Canaccord Genuity analyst remains optimistic about Passage Bio's prospects in the market for its gene therapy, suggesting that even conservative estimates indicate potential for the stock's value to rise from current levels. The analyst's stance is based on the belief that the large market for such treatments can support multiple successful products.
In other recent news, Passage Bio, Inc. has been making significant strides in its business operations and strategic efforts. The company has recently out-licensed treatments for GM1 gangliosidosis, Krabbe disease, and metachromatic leukodystrophy to GEMMA Biotherapeutics, Inc. This deal includes an upfront payment of $10 million and potential additional payments tied to business milestones.
In addition to this, Passage Bio has appointed Thomas Kassberg as a Class I director and member of the Audit Committee. Kassberg, who has extensive experience in the biotechnology field, was also granted non-incentive stock options as part of his compensation package.
Meanwhile, Passage Bio has been facing potential delisting from Nasdaq due to its share price falling below the minimum bid price requirement. The company is currently evaluating options to regain compliance with Nasdaq's listing requirements.
The company has also received approval from the U.S. Food and Drug Administration to evaluate its gene therapy treatment, PBFT02, for frontotemporal dementia patients with C9orf72 gene mutations.
Lastly, Passage Bio has reported an estimated impairment cost between $3.5 million and $5.5 million, in line with its recent sublease agreement and corporate restructuring efforts. These are recent developments in Passage Bio's ongoing efforts to address the unmet needs of the patient community.
InvestingPro Insights
As Canaccord Genuity maintains a positive outlook on Passage Bio Inc. (NASDAQ: PASG), it's worth noting some financial metrics and expert insights that could inform investors' perspectives. According to InvestingPro data, Passage Bio has a market capitalization of $45.12 million, reflecting its current valuation in the market. Despite the optimism surrounding their clinical trials, the company's P/E ratio stands at -0.55, indicating that the company is not currently profitable. Furthermore, the company's stock price has experienced a significant decrease over the last six months, with a price total return of -46.22%.
Delving into InvestingPro Tips, it's revealed that Passage Bio holds more cash than debt on its balance sheet, which is a positive sign of financial stability. However, the company is quickly burning through cash and has been flagged for weak gross profit margins. Analysts are not expecting the company to be profitable this year, which aligns with the negative P/E ratio. On the upside, Passage Bio's liquid assets do exceed its short-term obligations, providing some cushion for near-term financial operations. For investors seeking a more comprehensive analysis, there are additional InvestingPro Tips available on their platform, offering more nuanced perspectives on the company's financial health and outlook.
As the company forges ahead with its clinical trials, these financial insights can help investors weigh the potential risks and rewards associated with Passage Bio's stock. With the next earnings date set for November 12, 2024, stakeholders will be keenly watching for any developments that could sway the company's financial trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.